Background:
Post-stroke depression poses an important challenge for patients and delays reintegration to societal roles. Earlier identification of patients at higher risk for depression based on clinical imaging would allow a tailored treatment approach.
Methods:
We conducted machine-learning based lesion-symptom mapping (LSM) using a retrospective cohort of 477 patients with first-ever acute ischemic stroke (AIS) presenting to a large cerebrovascular center from 2013-2019 with mild motor impairment defined by mRS 0-2. Patient Health Questionnaire (PHQ-9) depression scale was collected within 60 days of index stroke. The location and volume of AIS lesions on brain MRI were analyzed using a machine-learning based algorithm coupled with the FreeSurfer parcellation package. LSM after random field theory-based multiple comparison correction was conducted to examine the association of AIS location and volume with PHQ-9 scale, adjusting for patient age, sex and NIHSS.
Results:
AIS in the right temporal, parietal, occipital lobes and the right basal ganglia were associated with depressive symptoms (Figure A). Sensitivity analysis excluding those with significant sleep disturbance (n=24) demonstrated that strokes in the right frontal and parietal lobes were associated with severe depression measured by PHQ-9>10 (Figure B).
Conclusions:
This hypothesis generating study was suggestive of a neuroanatomic basis for the development of post-stroke depression. Further studies in a larger dataset are needed to confirm these associations. The methods will help to predict those patients at higher risk for post-stroke depression, allowing for earlier intervention and recovery.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.